Close Menu

NEW YORK – iQX announced on Tuesday a collaboration between its subsidiary, Life Science Biosensor Diagnostics (LSBD), and Harvard University's Wyss Institute for Biologically Inspired Engineering to develop a SARS-CoV-2 antibody test.

Under the agreement, the partners will conduct a pilot study to integrate LSBD's Biosensor platform with an assay system developed by the Wyss Institute to detect IgM or IgG antibodies against SARS-CoV-2.

Financial and other terms of the deal were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.